Neurology & Brain Disorders Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

This study is exploring whether the recombinant zoster vaccine, commonly used to prevent shingles, can also reduce new cases of dementia in adults aged 76 and older. If the vaccine shows a protective effect, it could open the door to a new strategy for lowering dementia risk in older adults. The trial is currently enrolling participants in Finland, and its findings may help shape future dementia prevention efforts.

Patient Priorities Care Among Persons Living With Mild Cognitive Impairment and Dementia

This completed study tested an approach called Patient Priorities Care which focuses on aligning medical treatments with what matters most to people living with mild cognitive impairment or dementia. By tailoring care plans to patient goals, this method aims to improve quality of life and make treatment decisions more patient-centered. The results, gathered from multiple clinics across the United States, provide insights into how care can better support individuals’ personal priorities.

Multi-modal Neuroimaging in Alzheimer's Disease IMAP+

This research used advanced brain imaging and biomarker assessments to better track Alzheimer's disease progression. The study sought to find early signals in the brain and genetic markers that could improve diagnosis and monitoring of Alzheimer’s. Completed in France with 242 participants, its findings could help doctors detect changes earlier and tailor management strategies for people living with the disease.

Valacyclovir for Mild Cognitive Impairment

This phase 2 trial tested the antiviral medication valacyclovir in people with mild cognitive impairment, a condition that affects memory and thinking skills. The idea is to see if targeting viruses linked to Alzheimer’s disease might slow cognitive decline. Over 52 weeks, 50 participants in the United States took part, and the results may lead to new treatment options if the drug proves effective.

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

This ongoing study is examining whether non-invasive electrical brain stimulation can improve verbal learning and memory for people with typical and atypical forms of Alzheimer’s disease. Combined with language therapy, this approach aims to offer a new way to support communication skills beyond medications. Conducted at Johns Hopkins University, this research may provide additional tools to help people maintain language abilities.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.